Aktis Oncology launched on March 18 with significant financing in hand to advance a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.
Clovis Oncology Inc. entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH, a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need.